Oppenheimer Asset Management Inc. Buys 1,122 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oppenheimer Asset Management Inc. lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.0% in the third quarter, HoldingsChannel.com reports. The fund owned 56,155 shares of the medical equipment provider’s stock after acquiring an additional 1,122 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Intuitive Surgical were worth $27,587,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Creekmur Asset Management LLC increased its position in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the period. Ridgewood Investments LLC bought a new position in Intuitive Surgical during the second quarter valued at approximately $26,000. Delos Wealth Advisors LLC lifted its position in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Godsey & Gibb Inc. lifted its position in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the period. Finally, LRI Investments LLC bought a new position in Intuitive Surgical during the first quarter valued at approximately $30,000. 83.64% of the stock is owned by institutional investors.

Insider Transactions at Intuitive Surgical

In other news, insider Jamie Samath sold 22,903 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at approximately $4,597,425. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares in the company, valued at $402,519.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jamie Samath sold 22,903 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares of the company’s stock, valued at $4,597,425. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,178 shares of company stock worth $45,897,071. 0.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of research reports. Royal Bank of Canada upped their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday, October 18th. Robert W. Baird upped their target price on shares of Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Finally, Citigroup increased their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Stock Performance

ISRG stock traded down $0.53 during trading on Wednesday, hitting $536.54. 101,357 shares of the company’s stock traded hands, compared to its average volume of 1,453,387. Intuitive Surgical, Inc. has a 52 week low of $287.98 and a 52 week high of $542.59. The business has a fifty day simple moving average of $495.85 and a 200 day simple moving average of $455.08. The stock has a market capitalization of $191.10 billion, a price-to-earnings ratio of 86.35, a P/E/G ratio of 5.27 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Research analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.